Medical Oncology

, 30:338

Delayed response and survival from NovoTTF-100A in recurrent GBM

  • J. Lee Villano
  • Leena E. Williams
  • Karriem S. Watson
  • Nandini Ignatius
  • Marquess T. Wilson
  • Tibor Valyi-Nagy
  • Edward A. Michals
  • Herbert H. Engelhard
Short Communication

DOI: 10.1007/s12032-012-0338-1

Cite this article as:
Villano, J.L., Williams, L.E., Watson, K.S. et al. Med Oncol (2013) 30: 338. doi:10.1007/s12032-012-0338-1

Abstract

We present a 48-year-old male with recurrent glioblastoma (GBM) who was enrolled in the NovoTTF-100A landmark phase III study and has been on device for >6 years. During this time, his magnetic resonance images demonstrated initial growth followed by a slow decrease in enhancement with continued residual disease. Long-term survivors in patients with recurrent GBM are rare, especially in the absence of definitive local treatment such as surgery or radiosurgery. We present the clinical, imaging and pathological findings for this patient in relation to use of the NovoTTF-100A device.

Keywords

GlioblastomaBrain tumorTumor treatment fieldsRecurrent tumorSurvival

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • J. Lee Villano
    • 1
    • 2
    • 6
  • Leena E. Williams
    • 2
  • Karriem S. Watson
    • 2
  • Nandini Ignatius
    • 1
  • Marquess T. Wilson
    • 3
  • Tibor Valyi-Nagy
    • 4
  • Edward A. Michals
    • 5
  • Herbert H. Engelhard
    • 2
  1. 1.Department of MedicineUniversity of Illinois Medical CenterChicagoUSA
  2. 2.Department of NeurosurgeryUniversity of Illinois Medical CenterChicagoUSA
  3. 3.Department of NeurologyUniversity of Illinois Medical CenterChicagoUSA
  4. 4.Department of PathologyUniversity of Illinois Medical CenterChicagoUSA
  5. 5.Department of RadiologyUniversity of Illinois Medical CenterChicagoUSA
  6. 6.University of KentuckyLexingtonUSA